MYC and diffuse large B-cell lymphoma: They created the LymphGen algorithm to provide a probabilistic classification of tumors that translate from individual patients to genetic subtypes, allowing for the classification of DLBCL into seven genetic subtypes: 1) MCD, 2) N1, 3) A53, 4) BN2, 5) ST2, 6) EZB-MYC+, and 7) EZB-MYC-, with a patient prevalence of 8.7%, 1.7%, 5.8%, 13.3%, 6.4%, 5.9%, and 17.6%, respectively, and 5-year OS rates of 40%, 27%, 63%, 67%, 84%, 48%, and 82%, respectively 12.